Study identifier:5077IL/0118
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Steady State, Dose Unit Proportionality, and Food Effect Study Using Commercial Scale Sustained Release (SR) Quetiapine Fumarate (SEROQUEL)
schizophrenia
Phase 1
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
-
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|